Results 91 to 100 of about 48,812 (228)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes

, 2018
Peng Chen,1,* Fuchao Chen,2,* Benhong Zhou1,3 1Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People’s Republic of China; 2Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei ...
Chen P, Chen FC, Zhou BH
core  

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia

, 2016
Purpose: The aim of this study was to evaluate the cost-effectiveness of nivolumab versus ipilimumab for the treatment of previously untreated patients with BRAF-advanced melanoma (BRAF-AM) from an Australian health system perspective.
Liew, Danny, Gorelik, Alexandra, Kim, Hansoo, Bohensky, Megan A, Harrison, James P, Pasupathi, Kumar   +5 more
core   +1 more source

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

EJC Skin Cancer
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some.
Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan   +3 more
doaj   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non–small-cell lung cancer [PDF]

, 2017
Purpose \ud \ud Patients with squamous non-small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options. This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus ...
Doina Elena Ganea, Takayasu Kurata, Li, Mingshun, Tschaika, Marina, Aleksandra Szczesna, Reck, Martin, Myung-Ju Ahn, Han, Baohui, Claus-Peter Schneider, Von Pawel, Joachim, Ganea, Doina Elena, Mingshun Li, Martin Reck, Pablo Fernando Gonzalez Mella, Jacek Jassem, Li Zhang, Marina Tschaika, Govindan, Ramaswamy, Fadeeva, Natalia, Tamura, Tomohide, Lee, Ki Hyeong, Tomohide Tamura, Schneider, Claus-Peter, Vladimir Vladimirov, Postmus, Pieter E., Szczesna, Aleksandra, Ahn, Myung-Ju, Kurata, Takayasu, Fabrice Barlesi, Gonzalez Mella, Pablo Fernando, Joachim Von Pawel, O’Byrne, Kenneth J., Kenneth O’Byrne, Zhang, Li, Baohui Han, Jassem, Jacek, Vladimirov, Vladimir, Ramaswamy Govindan, Justin Kopit, Barlesi, Fabrice, Natalia Fadeeva, Ki Hyeong Lee, Kopit, Justin, Pieter E. Postmus   +43 more
core   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

, 2019
Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Zhang H, Khanal S
core  

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma

Case Reports in Dermatology, 2017
A 47-year-old female patient with rheumatoid arthritis (RA) treated with methotrexate, was diagnosed with metastatic melanoma. After surgical removal of the tumor, the patient started treatment with ipilimumab while methotrexate was stopped.
Nicoletta F. Jaberg-Bentele, Michael Kunz, Shatha Abuhammad, Reinhard Dummer   +3 more
doaj   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report

Case Reports in Oncology, 2017
Background: Antitumor immunotherapy has become a major player in cancer therapy. Ipilimumab is a humanized monoclonal antibody against the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an important downregulator of T-cell activation.
Reem Akel, Bilal Anouti, Arafat Tfayli
doaj   +1 more source